Latest Research

  • Consensus Statement
    | Open Access

    In this Consensus Statement, an expert panel from the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) recommends terminology for defining specific subgroups of individuals during the preclinical and early clinical phases of psoriatic arthritis to be used in research studies.

    • Lourdes M. Perez-Chada
    • , Rebecca H. Haberman
    •  & Jose U. Scher
  • Review Article |

    In this Review, the authors discuss macrophage activation syndrome (MAS) in relation to other cytokine storm scenarios, and provide a framework for understanding MAS within the spectrum of innate and adaptive immunity in the context of gain or loss of immune function.

    • Dennis McGonagle
    • , Athimalaipet V. Ramanan
    •  & Charlie Bridgewood
  • Review Article |

    Intervertebral disc (IVD) degeneration is a common condition associated with low back pain, but approved pharmacological interventions to prevent progression of IVD degeneration are lacking. This Review discusses the clinical progress and challenges of cell-based therapeutics for repairing the IVD.

    • Abbie L. A. Binch
    • , Joan C. Fitzgerald
    •  & Frank Barry
  • Review Article |

    In this Review, the authors examine how the definition and description of axial spondyloarthritis (axSpA) has evolved, most notably with the introduction of the concept of non-radiographic axSpA, and discuss the implications of these changes for diagnosis, classification and therapy.

    • Philip C. Robinson
    • , Sjef van der Linden
    •  & William J. Taylor
  • Review Article |

    Loss of B cell tolerance to autoantigens in systemic lupus erythematosus (SLE) is driven by TLR7, whereas TLR9 appears to protect against SLE by limiting the stimulatory activity of TLR7. The unique features of Toll-like receptor signalling in B cells implicate it as a therapeutic target in SLE.

    • Simon Fillatreau
    • , Benoît Manfroi
    •  & Thomas Dörner
  • Review Article |

    The immunogenicity of a biologic agent can have clinical consequences in terms of response to therapy and risk of adverse events. In this Review, the authors summarize the latest data on the immunogenicity of biologic agents for various rheumatic indications.

    • Vibeke Strand
    • , Joao Goncalves
    •  & John D. Isaacs
  • Review Article |

    For the past two decades, remission has been the focus of treatment strategies for rheumatoid arthritis (RA). This Review addresses the differences between remission and cure in RA and the underlying factors (‘drivers’) that trigger chronic inflammation and prevent cure.

    • Georg Schett
    • , Yoshiya Tanaka
    •  & John D. Isaacs
  • Perspective |

    In this article, the authors critically appraise the current model of opinion-based academia–industry interactions, and advocate for a realignment towards partnerships that foster innovation and knowledge.

    • Jose U. Scher
    •  & Georg Schett
  • Review Article |

    Nerve growth factor has been investigated as a therapeutic target for osteoarthritis and chronic low back pain, yet worries over adverse effects have stalled drug development. This Review provides an update on the current status of nerve growth factor inhibitors.

    • Barton L. Wise
    • , Matthias F. Seidel
    •  & Nancy E. Lane
  • Review Article |

    The development of osteoarthritis (OA) correlates with an increase in the number of senescent cells in joint tissues and the senescence-associated secretory phenotype is implicated in cartilage degradation and OA. Eliminating or altering senescent cells with senolytics or senomorphics could stop OA progression and pathogenesis.

    • Philip R. Coryell
    • , Brian O. Diekman
    •  & Richard F. Loeser
  • Review Article |

    Antinuclear antibodies (ANAs) are valuable biomarkers for various autoimmune rheumatic diseases and can be detected using various assays. This Review discusses the advantages and disadvantages of different ANA assays, to help in the understanding and interpretation of ANA test results.

    • Xavier Bossuyt
    • , Ellen De Langhe
    •  & Pier Luigi Meroni
  • Viewpoint |

    The COVID-19 pandemic led to unprecedented changes in rheumatology clinical practice. In this Viewpoint article, we asked five experts to describe their experiences of the COVID-19 pandemic, how their clinical practice has changed, and the opportunities and challenges that lie ahead.

    • Eloisa Bonfá
    • , Laure Gossec
    •  & Soumya Raychaudhuri
  • Review Article |

    In this Review, the authors describe the pathophysiological targets and clinical effects of new drugs currently being investigated for the treatment of osteoarthritis.

    • Augustin Latourte
    • , Margreet Kloppenburg
    •  & Pascal Richette
  • Review Article |

    The association of immune-mediated necrotizing myopathy (IMNM) with myositis-specific autoantibodies has led to the classification of three subclasses of IMNM and provided insight into the pathogenesis of, and treatment options for, these inflammatory myopathies.

    • Yves Allenbach
    • , Olivier Benveniste
    •  & Olivier Boyer
  • Review Article |

    In this Review, the authors discuss how new approaches, including imaging, tissue analysis and omics technologies, could be applied to identify patients with a poor prognosis and to predict response to treatment, thus enabling precision medicine and improving outcomes in psoriatic disease.

    • Deepak R. Jadon
    • , Carmel Stober
    •  & Oliver FitzGerald
  • Review Article |

    Fibromyalgia is a complex and common condition characterized by chronic widespread pain and numerous other symptoms. This Review outlines different clinical aspects of fibromyalgia, including the burden, diagnosis and treatment of this condition, and discusses various hypotheses of fibromyalgia etiopathogenesis.

    • Piercarlo Sarzi-Puttini
    • , Valeria Giorgi
    •  & Fabiola Atzeni